Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Health-care companies fell as traders retreated from some of the highest risk issues.

Nvidia shares have been under pressure since late January, when the release of a lower cost artificial intelligence (AI) ...

In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and ...

Roche (CH:ROG) shares rose as well, gaining 46in Zurich. Ozempic maker Novo Nordisk (DK:NOVO.B) (NVO), which along with Eli Lilly (LLY) dominates the weight-loss category, slumped 4%, though the ...

Vikrant Shrotriya, Corporate Vice President & Managing Director of Novo Nordisk India, during a session at India Today Conclave 2025, said that many celebrities may not want to admit to taking ...

U.S. equities were mixed at midday as the markets weighed a better-than-expected report on inflation and more tariff news.

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Investing.com – Denmark stocks were lower after the close on Wednesday, as losses in the Healthcare, Personal & Household Goods ...